Viatris Inc. is highlighted as one of the 12 Cheap Healthcare Stocks to Buy Now, operating globally with a focus on generics and specialty pharmaceuticals. The FDA approval of their generic iron sucrose injection marks a significant entry into the market with annual sales of $515 million. Positive late-stage trial results further strengthen their pipeline for future growth.

Viatris Inc. (VTRS) is expanding its presence in the healthcare market through innovation and complex generics. The CEO emphasizes the importance of a diversified portfolio and successful commercial execution for new product launches. While VTRS shows investment potential, there are AI stocks with greater upside potential and less downside risk.

For investors interested in the healthcare sector, Viatris Inc. offers a cost-effective option with a growing late-stage pipeline and successful Phase 3 trial results. The company’s strategic focus on complex generics and specialty products positions it as an innovation-driven business. Consider exploring AI stocks for potentially higher returns and lower risks in the current market.

Read more at Yahoo Finance: Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light